drugset / Trial / NCT04501705
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
NaSingle-groupOpen-labelTreatment
Summary
Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.
Timeline
- Start
- 2020-08-18
- Primary completion
- 2025-08-31
- Completion
- 2025-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |